Similar articles

• Chemical xenogenization of experimental tumors.

  Puccetti P, Romani L, Fioretti MC. Puccetti P, et al. Cancer Metastasis Rev. 1987;6(2):93-111. doi: 10.1007/BF00052845. Cancer Metastasis Rev. 1987. PMID: 3297373 Review.
• Drug-mediated changes of tumour cell immunogenicity and antigenicity.

  Puccetti P, Romani L, Taramelli D, Bonmassar E, Fioretti MC. Puccetti P, et al. Int J Tissue React. 1982;4(3):189-99. Int J Tissue React. 1982. PMID: 6183194 No abstract available.
• Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.

  Franzese O, Torino F, Fuggetta MP, Aquino A, Roselli M, Bonmassar E, Giuliani A, D'Atri S. Franzese O, et al. Oncotarget. 2017 Jun 20;8(25):41641-41669. doi: 10.18632/oncotarget.16335. Oncotarget. 2017. PMID: 28404974 Free PMC article. Review.
• Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.

  Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y. Toda M, et al. Cancer Gene Ther. 2002 Apr;9(4):356-64. doi: 10.1038/sj.cgt.7700446. Cancer Gene Ther. 2002. PMID: 11960286
• Relationship of success in classical immunotherapy to the relative immunorejective strength of the tumor.

  Reif AE. Reif AE. J Natl Cancer Inst. 1986 Oct;77(4):899-908. J Natl Cancer Inst. 1986. PMID: 3020300